Binding kinetics of triclosan (Irgasan®) to alloplastic vascular grafts: An in vitro study

Annals of Vascular Surgery

Volumn 14, Issue 4, 2000, Pages 370-375

  Hernandez Richter T ^a   Schardey, H M ^a   Lohlein F ^a   Fleischer, C T ^a   Walli, A K ^a   Boos, K S ^a   Schildberg, F W ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IRGASAN; TRICLOSAN;

ALLOGRAFT; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BLOOD VESSEL GRAFT; CANDIDA ALBICANS; CONTROLLED STUDY; DEVICE; DRUG BINDING; ENTEROCOCCUS FAECIUM; IN VITRO STUDY; KINETICS; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

EID: 0343517132     PISSN: 08905096     EISSN: None     Source Type: Journal    
DOI: 10.1007/s100169910065     Document Type: Article

References (16)

1. Spartera C, Morettini G, Bafile G, Di Cesare E, Alage G, Ventura M. Diagnostic imaging techniques and vascular graft infections. Eur J Vasc Endorasc Surg 1997;14(Suppl.A): 24-26.
2. Regös J, Zak O, Solf R, Vischer WA, Weirich EG. Antimicrobial spectrum of Triclosan, a broad-spectrum antimicrobial agent for topical application. Dermatologica 1979;158:72-79.
3. Boos KS, Grimm CH. High-performance liquid chromatography integrated solid-phase extraction in bioanalysis using restricted access precolumn packings. Trends Anal Chem 1999;18:175-180.
4. Manouguian S. Unsere klinische Erfahrung mit der neuen antimikrobiell beschichteten Inter-Gard-IGK/AM-Gefäβprothese bei der chirurgischen Behandlung des tiefen Wundinfektes mit Beteiligung des Kunststoff-Bypasses: Bericht über zwei Fälle. Zentralbl Chir 1996;121:768-772.
5. Bhargava H, Leonard PA., Triclosan: application and safety. Am J Infect Control 1996;24(3):209-218.
6. Torsello G. Kommentar auf Anforderung der Schriftleitung zum Beitrag "Unsere klinische Erfahrung mit der neuen antimikrobiell beschichteten Inter-Gard-IGK/AM-Gefäβprothese bei der chirurgischen Behandlung des tiefen Wundinfektes mit Beteiligung des Kunststoff-Bypasses: Bericht über zwei Fälle." Zentralbl Chir 1996;121:772-773.
7. Chervu A, Moore WS, Chvapil M, Hendersson T. Efficacy and duration of antistaphylococcal activity comparing three antibiotics bonded to dacron vascular grafts with a collagen release system. J Vasc Surg 1991;13:897-901.
8. Greco RS, Harvey RA. The role of antibiotic bonding in the prevention of vascular prosthetic infection. Ann Surg 1982; 195:168-171.
9. Greco RS. Utilising vascular prosthesis for dry delivery. Eur J Vasc Surg 1991;5:753-757.
10. Harvey RA, Greco RS. The noncovalent bonding of antibiotic to a PTFE graft. Ann Surg 1981;194:642-647.
11. Moore WS, Chvapil M, Seiffert G, Keown K. Developement of an infection-resistant vascular prosthesis. Arch Surg 1981; 116:1403-1407.
12. Malassiney P, Goiëau-Brissonnière O, Coggia M, Pechere JC. Rifampicin loading of vascular grafts. J Antimicrob Chemother 1996;37:1121-1129.
13. Chervu A, Moore WS, Gelabert HA, Colburn MD, Chvapil M. Prevention of graft infection by use of prostheses bonded with a rifampin-collagen release system. J Vasc Surg 1991; 14:521-524.
14. D'Addato M, Curti T, Freyrie A, Abus GB, Bertini D, Biasi GM. Prevention of early graft infection with rifampicin-bonded gelseal graft: a multicenter experimental study. Cardiovasc Surg 1994;2:254-258.
15. D'Addato M, Curti T, Freyrie A. The rifampicin-bonded gelseal graft. Eur J Vasc Endovasc Surg 1997;14A:15-17.
16. Koskas F, Goëau-Brissonnière O, Pechere JC. Prevention of early wound and graft infection with rifampicin-bonded knitted polyester grafts: results of the rifampicin-bonded grafts European trial (RBET). Presented at Rifampicin-Bonded Grafts European Trial, Paris, May 12-13, 1995.